4-(3,5-dioxo-pyrazolidin-1-yl)-benzonitrile | 820238-58-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3,5-dioxo-pyrazolidin-1-yl)-benzonitrile
• 英文别名: Benzonitrile, 4-(3,5-dioxo-1-pyrazolidinyl)-；4-(3,5-dioxopyrazolidin-1-yl)benzonitrile
• CAS: 820238-58-2
• 化学式: C₁₀H₇N₃O₂
• 分子量: 201.184
• InChiKey: QINHGXJVMVHYAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3,5-dioxo-pyrazolidin-1-yl)-benzonitrile 、 香草醛 在 吡啶 作用下， 以 乙醇 为溶剂， 反应 10.0h， 生成 4-[4-[(4-hydroxy-3-methoxyphenyl)methylidene]-3,5-dioxopyrazolidin-1-yl]benzonitrile
  参考文献：
  名称：

  QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors

  摘要：

  Individuals with Down syndrome (DS) suffer from mental retardation. Overexpression and the resulting increased specific activity of Dyrk1A kinase located on chromosome 21 cause a learning and memory deficit in Dyrk1A transgenic mice. To search for therapeutic agents with Dyrk1A inhibition activity, previously we obtained HCD160 as a new hit compound for Dyrk1A inhibition. In the present study, we synthesized 34 HCD160 derivatives to investigate the quantitative structure-activity relationship (QSAR). This analysis could provide important information for novel drug discovery for treatment of DS related learning and memory deficits. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.062
• 作为产物：
  描述：

  在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-(3,5-dioxo-pyrazolidin-1-yl)-benzonitrile
  参考文献：
  名称：

  QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors

  摘要：

  Individuals with Down syndrome (DS) suffer from mental retardation. Overexpression and the resulting increased specific activity of Dyrk1A kinase located on chromosome 21 cause a learning and memory deficit in Dyrk1A transgenic mice. To search for therapeutic agents with Dyrk1A inhibition activity, previously we obtained HCD160 as a new hit compound for Dyrk1A inhibition. In the present study, we synthesized 34 HCD160 derivatives to investigate the quantitative structure-activity relationship (QSAR). This analysis could provide important information for novel drug discovery for treatment of DS related learning and memory deficits. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.062

文献信息

• [EN] PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS<br/>[FR] DERIVES DE PYRAZOLIDINEDIONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'AGREGATION DES PLAQUETTES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2005002574A1

  公开（公告）日：2005-01-13

  Pyrazolidinedione derivatives of the general formula (I), wherein R1 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; and R2 is aryl or heteroaryl; tautomers thereof; geometric isomers thereof and tautomers of these geometric isomers, including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric isomers, or tautomers thereof; pharmaceutically acceptable acid addition salts of compounds which are basic; pharmaceutically acceptable salts of compounds containing acidic groups with bases; pharmaceutically acceptable esters of compounds containing hydroxy or carboxy groups; prodrugs of compounds in which a prodrug forming group is present; as well as hydrates or solvates thereof; are active as platelet adenosine diphosphate receptor antagonists and can be used for the prevention and/or treatment of peripheral vascular, of visceral-, hepaticand renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, particularly thrombosis, and, respectively, for the manufacture of corresponding medicaments. Some, albeit not all, of the compounds of the above formula (I) are novel.

  一般公式（I）的吡唑烷二酮衍生物，其中R1是氢，可选地取代烷基，环烷基，芳基，芳烷基，杂芳基或杂芳烷基；R2是芳基或杂芳基；其互变异构体；其几何异构体及这些几何异构体的互变异构体，包括公式（I）的单个化合物的混合物，或其互变异构体，及其几何异构体，或其互变异构体；药物可接受的酸加成盐基本化合物；含有酸性基团的化合物与碱的药物可接受盐；含有羟基或羧基的化合物的药物可接受酯；以及存在前药形成基团的化合物的前药；以及它们的 hydrates 或 solvates；作为血小板二磷酸腺苷受体拮抗剂活性，可用于预防或治疗外周血管疾病，内脏、肝脏和肾脏血管疾病，心血管疾病和脑血管疾病或与血小板聚集相关的病症，尤其是血栓症，并且分别用于制造相应的药物。上述公式（I）中的一些化合物是新颖的，但并非全部。
• Pyrazolidinedione derivatives
  申请人：Fretz Heinz

  公开号：US20070037846A1

  公开（公告）日：2007-02-15

  The present invention relates to compounds of alkylidene pyrazolidinedione derivatives, which are effective platelet ADP receptor antagonists that prevent platelet aggregation and thrombosis. Thus, the present invention also relates to pharmaceutical compositions that contain the compounds as well as methods of preventing or treating peripheral, visceral, hepatic, renal, cardio- and cerebro-vascular diseases and conditions that are associated with platelet aggregation, including thrombosis, in humans and other mammals. The present invention further provides a process for manufacturing the alkylidene pyrazolidinedione derivatives.

  本发明涉及烷基亚胺吡唑啉二酮衍生物化合物，其为有效的血小板ADP受体拮抗剂，可预防血小板聚集和血栓形成。因此，本发明还涉及包含该化合物的制药组合物，以及用于预防或治疗与血小板聚集有关的外周、内脏、肝、肾、心血管和脑血管疾病和病状的方法，包括血栓形成，在人类和其他哺乳动物中。本发明还提供一种制造烷基亚胺吡唑啉二酮衍生物的方法。
• PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1638540A2

  公开（公告）日：2006-03-29
• [EN] PYRAZOLIDINEDIONE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLIDINEDIONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2005000281A2

  公开（公告）日：2005-01-06

  Pyrazolidinedione derivatives of the general formula (I), wherein R1 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or alkanoyl; and R2 is aryl or heteroaryl; tautomers thereof; geometric isomers thereof and tautomers of these geometric isomers, including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric isomers, or tautomers thereof, pharmaceutically acceptable acid addition salts of compounds which are basic; pharmaceutically acceptable salts of compounds containing acidic groups with bases; pharmaceutically acceptable esters of compounds containing hydroxy or carboxy groups; prodrugs of compounds in which a prodrug forming group is present; as well as hydrates or solvates thereof; are active as platelet adenosine diphosphate receptor antagonists and can be used for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, particularly thrombosis, and, respectively, for the manufacture of corresponding medicaments. Some, albeit not all, of the compounds of the above formula (I) are novel.
• QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors
  作者：Kyung Ah Koo、Nam Doo Kim、Yong Sog Chon、Min-Su Jung、Burm-Jong Lee、Jung Ho Kim、Woo-Joo Song

  DOI：10.1016/j.bmcl.2009.02.062

  日期：2009.4

  Individuals with Down syndrome (DS) suffer from mental retardation. Overexpression and the resulting increased specific activity of Dyrk1A kinase located on chromosome 21 cause a learning and memory deficit in Dyrk1A transgenic mice. To search for therapeutic agents with Dyrk1A inhibition activity, previously we obtained HCD160 as a new hit compound for Dyrk1A inhibition. In the present study, we synthesized 34 HCD160 derivatives to investigate the quantitative structure-activity relationship (QSAR). This analysis could provide important information for novel drug discovery for treatment of DS related learning and memory deficits. (C) 2009 Elsevier Ltd. All rights reserved.